Coronary Heart Disease - Leading Cause Of Death In Diabetes Patients
Millennium Research Group (MRG) has conducted a detailed analysis of the diabetes management market in its US Markets for Diabetic Vascular Disease Treatment Devices 2007 report. The analysis reveals that coronary heart disease is the leading cause of death among diabetics. Every year in the US, heart disease is responsible for over 65% of the deaths of diabetics. This number will rise as the population ages and the prevalence of diabetes grows at almost 3% per year. Due to the large number of coronary-related deaths, coronary revascularization has become an increasingly important method of extending diabetic patients' lives. Consequently, the market for coronary revascularization devices in diabetics will exceed $1.3 billion by 2011.
"While medical management of coronary heart disease with pharmaceutical interventions is widespread in diabetic patients, many cases necessitate mechanical restoration of adequate blood flow, termed revascularization," says Darren Navarro, Analyst at MRG. "Coronary revascularization can be achieved either through endovascular (from within the blood vessel) or open surgical means. The choice of which coronary revascularization strategy is best for diabetic patients has always been complex due to their afflicted vasculature and slower recovery from treatments."
The prevalence of diabetes has increased dramatically in the US over the past two decades as the result of poor lifestyle habits and increased obesity and hypertension in the population. In 2007, over 21 million people in the US will have diabetes, with close to 30% remaining undiagnosed.
The US Markets for Diabetic Vascular Disease Treatment Devices 2007 report includes coverage of industry competitors including Abbott Vascular, Angiodynamics, Arrow International, Atrium Medical, Boston Scientific, C.R. Bard, Cook, Cordis, Datascope, Deltec (Smiths Medical), Edwards Lifesciences, ev3, Fox Hollow, Kendall (Covidien, formerly Tyco Healthcare), Medcomp, Medtronic, Microtherapeutics, Spectranetics, Spire Medical, and W.L. Gore.